Table 2.
Group comparisons between those who had RLS at baseline, developed de novo RLS, and never developed RLS.
| Baseline RLS (n = 27) [A] | De Novo RLS (n = 35) [B] | Never Developed RLS (n = 35) [C] | Significance* | |
|---|---|---|---|---|
| Age at PRC admission (years) | 46.630 (12.555) | 54.857 (12.486) | 54.829 (13.587) | B,C>A |
| MME (mean) | 53.900 (61.407) | 50.686 (48.034) | 34.235 (35.080) | B>C |
| MME (median) | 22.500 | 38.000 | 22.750 | B>C |
| Duration opioid use (months) | 90.000 (101.032) | 51.478 (53.819) | 116.444 (113.498) | NS |
| Sex | A>B,C | |||
| Female | 22 (81.5%) | 19 (54.3%) | 19 (54.3%) | |
| Male | 5 (18.5%) | 16 (45.7%) | 16 (45.7%) | |
| MME > 20 | B>A,C | |||
| No | 14 (51.9%) | 6 (17.1%) | 16 (45.7%) | |
| Yes | 13 (48.1%) | 29 (82.9%) | 19 (54.3%) | |
| Alpha-2-delta ligand use | NS | |||
| No | 11 (40.7%) | 18 (51.4%) | 18 (51.4%) | |
| Yes | 16 (59.3%) | 17 (48.6%) | 17 (48.6%) | |
| MedWorsenRLS | A>B,C | |||
| No | 11 (40.7%) | 27 (77.1%) | 24 (68.6%) | |
| Yes | 16 (59.3%) | 8 (22.9%) | 11 (31.4%) | |
| Timepoint taper completed | NS | |||
| Admission | 1 (3.7%) | 2 (5.7%) | 2 (5.7%) | |
| Midpoint | 18 (66.7%) | 19 (54.3%) | 24 (68.6%) | |
| Dismissal | 8 (29.6%) | 14 (40.0%) | 9 (25.7%) | |
| Opioid type | NS | |||
| Nonsynthetic | 1 (3.7%) | 3 (8.6%) | 0 (0.0%) | |
| Synthetic | 26 (96.3%) | 32 (91.4%) | 35 (100.0%) | |
| Peak COWS Score | 5.000 (2.951) | 4.207 (2.664) | 3.231 (3.637) | NS |
*
Significance indicates P < .05 at subgroup level comparisons. COWS = Clinical Opiate Withdrawal Scale, DC = dismissal from PRC, IRLSS = International Restless Leg Study Group Severity Scale, MedWorsenRLS = serotonergic or anticholinergic medication use, MME = milligram morphine equivalent, NS = Not significant, PRC = Mayo Clinic Pain Rehabilitation Center.